ANALYTICAL AND STATISTICAL STUDY OF THE RANGE OF ANTIFUNGAL MEDICINES OF LOCAL ACTION

. Fungal skin lesions occur in every third person on our planet, which is an important social and medical problem. Therefore, to effectively combat fungal infections, it is advisable to conduct a marketing analysis of antifungal agents for local use, which are presented in the pharmaceutical market of Ukraine, to determine the availability of convenient dosage forms and expand production of new drugs not only synthetic but also based on plant raw materials. From year to year in the world

From year to year in the world there is a rapid increase in the number of cases of fungal diseases of the skin and its appendages. According to WHO statistics, every third person on our planet is diagnosed with mycosis [1], and the incidence of fungal infections increases with age 2.5 times every 10 years [5]. This is due to adverse environmental conditions, reduced immune systems, long-term and not always rational use of broad-spectrum antibacterial agents, glucocorticosteroids, cytostatics and contraceptives. Analysis of literature sources showed [4,6] that dermatomycoses are characterized not only by a long course, but also by high resistance to treatment and, as a consequence, the chronicity of the pathological process.
For modern medicine and pharmacy, the treatment of dermatomycoses is one of the most pressing and common problems. It needs new scientifically and economically sound approaches to the organization of medical care in Ukraine, which will meet global requirements, by providing quality, safe and effective antifungal drugs, and the formation of the necessary range in pharmacies.
Therefore, it is appropriate and relevant to conduct marketing research of drugs for the treatment of dermatomycoses.
The aim. To study the range of antifungal drugs for the treatment of local fungal infections, presented on the domestic pharmaceutical market, and to determine the prospects for the development of new drugs with a possible increase.
Research methods. In the course of marketing analysis of antifungal drugs registered on the pharmaceutical market of Ukraine, generalized data of the State Register of Medicinal Products of Ukraine [2] and the Internet resource of the search system "Morion" "Compendium-online 2019" [3] were used. Analytical, statistical and comparative methods were used to conduct the study.
Research results and their discussion. Based on the content analysis of the State Register of Medicinal Products of Ukraine and the electronic directory "Compendium-online 2019" [2,3] it became known that the range of antifungal drugs of local action is represented by 108 trade names (TN). According to the international ATC classification, the drug arsenal of drugs for the pharmacotherapy of dermatomycoses belongs to group D01A "Antifungal drugs for topical use" and three main subgroups: D01A A -Antibiotics (7 TN), D01A C -Imidazole derivatives and (49 TN), D01A E -Other topical antifungals (52 TN), accounting for 6.5%, 47.1% and 46.4%, respectively.
According to the structure of the range of antifungal drugs according to the PBX classification, the most saturated group is naftifine (D01A E22), which included 21 drugs. The second place in terms of the number of drugs was taken by the ketoconazole group (D01A C08) -17 trade names; third placeterbinafine group (D01A E15) -14 names; fourththe clotrimazole group (D01A C01), which has 12 drugs. The share of drugs of these four groups was 59.4% of the total range of antifungal drugs for topical use.
Conclusions. The modern pharmaceutical market of antifungal drugs is represented by 108 trade names. It was found that 45.4% of drugs are imported to the pharmaceutical market, and the Ukrainian consumer is provided with 54.6% of domestic drugs. Four leaders among the group D01A "Topical Antifungals" are naftifine, ketoconazole, terbinafine and clotrimazole. It should be noted that almost all drugs in this group are monocomponent and of synthetic origin.
Therefore, in order to expand the range, it is advisable to create appropriate conditions for Ukrainian producers to create antifungal drugs based on raw materials of plant origin.